Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Memorial Sloan Kettering Cancer Center · Hôpital Larrey · +27 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,427
total citations
- FWCI
- 107.64
- Percentile
- 100%
- References
- 36
Citations per year
Authors
30- NANaiyer A. RizviCorresponding
Memorial Sloan Kettering Cancer Center
- JMJulien Mazières
Hôpital Larrey, Centre Hospitalier Universitaire de Toulouse
- DPDavid Planchard
Institut Gustave Roussy
- TEThomas E. Stinchcombe
University of North Carolina at Chapel Hill
- GKGrace K. Dy
Roswell Park Comprehensive Cancer Center
Topics & keywords
Topics
Keywords
- Nivolumab
- Medicine
- Internal medicine
- Refractory (planetary science)
- Pneumonitis
- Clinical endpoint
- Lung cancer
- Adverse effect
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.